JonesTrading analyst Soumit Roy has maintained their bullish stance on NUVB stock, giving a Buy rating today.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Soumit Roy has given his Buy rating due to a combination of factors including Nuvation Bio’s successful market penetration with their drug Ibtrozi, which has shown promising adoption rates among newly diagnosed ROS1+ NSCLC patients. The company’s product revenue exceeded expectations, indicating strong commercial performance.
Additionally, the anticipated expansion into European markets and the ongoing pivotal trials for safusidenib in high-grade IDH1-mutant glioma patients further bolster the company’s growth prospects. The management’s strategic engagement with key accounts and the comprehensive payer coverage also contribute to a positive outlook, supporting the Buy rating.
According to TipRanks, Roy is an analyst with an average return of -17.3% and a 26.41% success rate. Roy covers the Healthcare sector, focusing on stocks such as Cullinan Management, Protara Therapeutics, and CG Oncology, Inc..
In another report released today, Citizens JMP also maintained a Buy rating on the stock with a $8.00 price target.